Wall Street Zen lowered shares of 4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) from a sell rating to a strong sell rating in a report released on Saturday morning,Wall Street Zen reports.
Several other equities research analysts have also commented on the stock. Cantor Fitzgerald upgraded shares of 4D Molecular Therapeutics from a “neutral” rating to an “overweight” rating and set a $20.00 price objective on the stock in a research report on Monday, September 14th. HC Wainwright reissued a “buy” rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a research note on Thursday, October 22nd. B. Riley Financial restated a “buy” rating on shares of 4D Molecular Therapeutics in a report on Monday, August 17th. Citigroup reissued a “buy” rating on shares of 4D Molecular Therapeutics in a report on Thursday, October 22nd. Finally, Bank of America upped their price objective on 4D Molecular Therapeutics from $29.00 to $33.00 and gave the company a “buy” rating in a research report on Tuesday, September 29th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $30.22.
Read Our Latest Stock Analysis on 4D Molecular Therapeutics
4D Molecular Therapeutics Trading Down 4.6%
Shares of 4D Molecular Therapeutics stock opened at $10.23 on Friday. The company has a 50-day moving average of $12.80 and a two-hundred day moving average of $11.11. The stock has a market cap of $576.77 million, a PE ratio of -3.79 and a beta of 2.92. The company has a current ratio of 6.15, a quick ratio of 6.15 and a debt-to-equity ratio of 0.06. 4D Molecular Therapeutics has a 12-month low of $6.96 and a 12-month high of $16.93.
4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.03). 4D Molecular Therapeutics had a negative return on equity of 47.06% and a negative net margin of 208.57%. The firm had revenue of $4.14 million during the quarter, compared to analyst estimates of $4.13 million. On average, research analysts anticipate that 4D Molecular Therapeutics will post -4.21 EPS for the current fiscal year.
Insider Buying and Selling
In other 4D Molecular Therapeutics news, insider David Kirn sold 58,333 shares of the business’s stock in a transaction on Monday, October 5th. The stock was sold at an average price of $12.92, for a total value of $753,662.36. Following the completion of the transaction, the insider directly owned 709,153 shares in the company, valued at approximately $9,162,256.76. The trade was a 7.60% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last three months, insiders have sold 120,520 shares of company stock valued at $1,615,978. 7.90% of the stock is currently owned by insiders.
Institutional Investors Weigh In On 4D Molecular Therapeutics
Hedge funds have recently made changes to their positions in the business. American Century Companies Inc. increased its stake in shares of 4D Molecular Therapeutics by 12.2% during the 3rd quarter. American Century Companies Inc. now owns 127,965 shares of the company’s stock valued at $1,831,000 after acquiring an additional 13,965 shares during the last quarter. Aquatic Capital Management LLC purchased a new position in shares of 4D Molecular Therapeutics during the 3rd quarter worth about $814,000. Empowered Funds LLC acquired a new stake in shares of 4D Molecular Therapeutics in the third quarter worth approximately $352,000. Voya Investment Management LLC boosted its position in shares of 4D Molecular Therapeutics by 36.9% in the third quarter. Voya Investment Management LLC now owns 191,868 shares of the company’s stock worth $2,746,000 after acquiring an additional 51,668 shares during the last quarter. Finally, AlphaCore Capital LLC acquired a new stake in shares of 4D Molecular Therapeutics in the third quarter worth approximately $279,000. Institutional investors and hedge funds own 99.27% of the company’s stock.
4D Molecular Therapeutics Company Profile
4D Molecular Therapeutics, Inc. is a biotechnology company developing genetic medicines for serious diseases. Its research focuses on adeno-associated virus (AAV) gene therapies, which use engineered viral vectors to deliver therapeutic genetic material to cells. The company’s proprietary Therapeutic Vector Evolution platform is designed to create AAV vectors with targeted properties, including the ability to reach specific tissues. Its investigational programs have included treatments for retinal diseases, cystic fibrosis and Fabry disease.
Featured Articles
- Five stocks we like better than 4D Molecular Therapeutics
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for 4D Molecular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D Molecular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
